Switch theme
Sign up to access all valuation multiples
Panion & Bf Biotech Inc operates as a biotech and pharmaceutical company. The company along with its subsidiaries is mainly engaged in the manufacture and sales of pharmaceutical, cosmeceutical, diagnostic, medical device, and active pharmaceutical ingredients. It has four core business groups such as disease treatment, disease prevention, disease diagnosis, and delayed aging. It has two geographic segments Taiwan segment and China, Hong Kong, and Macau segment. It generates a majority of its revenue from the Taiwan segment.
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Panion & Bf Biotech has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Panion & Bf Biotech achieved revenue of $57.4M and an EBITDA of $10.7M.
Panion & Bf Biotech expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Panion & Bf Biotech valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $73.2M | $57.4M | n/a | n/a | XXX |
| Gross Profit | $27.8M | $40.2M | $29.7M | XXX | XXX |
| Gross Margin | 38% | 70% | NaN% | XXX | XXX |
| EBITDA | $15.4M | $10.7M | n/a | n/a | XXX |
| EBITDA Margin | 21% | 19% | NaN% | NaN% | XXX |
| Net Profit | $3.2M | $5.6M | $2.4M | XXX | XXX |
| Net Margin | 4% | 10% | NaN% | XXX | XXX |
| Net Debt | $4.2M | n/a | $4.3M | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, Panion & Bf Biotech's stock price is TWD 87 (or $3).
Panion & Bf Biotech has current market cap of TWD 7.4B (or $226M), and EV of TWD 7.7B (or $234M).
See Panion & Bf Biotech trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $234M | $226M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, Panion & Bf Biotech has market cap of $226M and EV of $234M.
Panion & Bf Biotech's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Panion & Bf Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Panion & Bf Biotech and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $234M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpPanion & Bf Biotech's NTM/LTM revenue growth is n/a
Panion & Bf Biotech's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Panion & Bf Biotech's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Panion & Bf Biotech's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Panion & Bf Biotech and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 23% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 9% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 12% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 44% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Panion & Bf Biotech acquired XXX companies to date.
Last acquisition by Panion & Bf Biotech was XXXXXXXX, XXXXX XXXXX XXXXXX . Panion & Bf Biotech acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Panion & Bf Biotech founded? | Panion & Bf Biotech was founded in 1976. |
| Where is Panion & Bf Biotech headquartered? | Panion & Bf Biotech is headquartered in Taiwan. |
| How many employees does Panion & Bf Biotech have? | As of today, Panion & Bf Biotech has 394 employees. |
| Is Panion & Bf Biotech publicy listed? | Yes, Panion & Bf Biotech is a public company listed on TAI. |
| What is the stock symbol of Panion & Bf Biotech? | Panion & Bf Biotech trades under 1760 ticker. |
| When did Panion & Bf Biotech go public? | Panion & Bf Biotech went public in 2004. |
| Who are competitors of Panion & Bf Biotech? | Similar companies to Panion & Bf Biotech include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Panion & Bf Biotech? | Panion & Bf Biotech's current market cap is $226M |
| Is Panion & Bf Biotech profitable? | Yes, Panion & Bf Biotech is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
